Aileron Therapeutics ALRN

$ 1.93 -8.96%

Quarterly report 2024-Q3
added 11-14-2024

Aileron Therapeutics Balance Sheet 2011-2024 | ALRN

Annual Balance Sheet Aileron Therapeutics

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-	-3.44 M	-6.66 M	-279 K	-5.29 M	-11.9 M	-20.7 M	-3.77 M	-	-	-	-
Long Term Debt	-	-	69 K	219 K	-	-	-	-	-	-	-	-	-
Long Term Debt Current	48 K	33 K	93 K	-	446 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	4.59 M	5.34 M	-	130 M	97.7 M	-	-	-	-
Total Current Liabilities	4.38 M	3.38 M	4.51 M	3.96 M	5.84 M	5.37 M	4.89 M	-	-	-	-	-	-
Total Liabilities	7.71 M	3.38 M	4.58 M	4.18 M	10.4 M	10.7 M	4.89 M	134 M	100 M	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-289 M	-273 M	-245 M	-219 M	-198 M	-168 M	-137 M	-114 M	-96.2 M	-	-	-	-
Total Assets	106 M	22 M	48.5 M	16.3 M	26.5 M	30.3 M	52.7 M	22 M	5.94 M	-	-	-	-
Cash and Cash Equivalents	17.3 M	5.19 M	3.6 M	7.05 M	5.31 M	10.6 M	11.9 M	-	-	-	-	-	-
Book Value	98.3 M	18.6 M	43.9 M	12.2 M	16 M	19.6 M	47.8 M	-112 M	-94.3 M	-	-	-	-
Total Shareholders Equity	6.89 M	18.6 M	43.9 M	12.2 M	16 M	19.6 M	47.8 M	-112 M	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Aileron Therapeutics

	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	69 K	99 K	128 K	124 K	-	4.2 M	4.33 M	4.46 M	4.59 M	4.59 M	4.59 M	4.59 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	8.98 M	8.38 M	7.86 M	7.71 M	1.62 M	1.2 M	2.88 M	3.38 M	4.54 M	5.15 M	4.15 M	4.58 M	4.66 M	4.4 M	3.25 M	4.18 M	4.18 M	4.18 M	4.18 M	10.4 M	10.4 M	10.4 M	10.4 M	10.7 M	10.7 M	10.7 M	10.7 M	4.89 M	4.89 M	4.89 M	4.89 M	4.08 M	4.08 M	4.08 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-310 M	-305 M	-296 M	-289 M	-281 M	-279 M	-278 M	-273 M	-268 M	-262 M	-254 M	-245 M	-239 M	-232 M	-226 M	-219 M	-219 M	-219 M	-219 M	-198 M	-198 M	-198 M	-198 M	-168 M	-168 M	-168 M	-168 M	-137 M	-137 M	-137 M	-137 M	-114 M	-114 M	-114 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	104 M	109 M	99.2 M	106 M	12.8 M	14 M	17.2 M	22 M	27.2 M	33.8 M	40.3 M	48.5 M	54.8 M	60.5 M	64.7 M	16.3 M	16.3 M	16.3 M	16.3 M	26.5 M	26.5 M	26.5 M	26.5 M	30.3 M	30.3 M	30.3 M	30.3 M	52.7 M	52.7 M	52.7 M	52.7 M	22 M	22 M	22 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	17.7 M	21.9 M	12 M	17.3 M	12.1 M	13.2 M	7.78 M	5.19 M	4.84 M	7.63 M	7.45 M	3.6 M	7.6 M	10.7 M	19.3 M	7.05 M	7.05 M	7.05 M	7.05 M	5.31 M	5.31 M	5.31 M	5.31 M	10.6 M	10.6 M	10.6 M	10.6 M	11.9 M	11.9 M	11.9 M	11.9 M	20.7 M	20.7 M	20.7 M	-	3.77 M	-	-	-	6.21 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	95.2 M	101 M	91.3 M	98.3 M	11.2 M	12.8 M	14.3 M	18.6 M	22.7 M	28.6 M	36.1 M	43.9 M	50.1 M	56.1 M	61.4 M	12.2 M	12.2 M	12.2 M	12.2 M	16 M	16 M	16 M	16 M	19.6 M	19.6 M	19.6 M	19.6 M	47.8 M	47.8 M	47.8 M	47.8 M	17.9 M	17.9 M	17.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	-	-	-	11.2 M	12.8 M	14.3 M	18.6 M	22.7 M	28.6 M	36.1 M	43.9 M	50.1 M	56.1 M	61.4 M	12.2 M	12.2 M	12.2 M	12.2 M	16 M	16 M	16 M	16 M	19.6 M	19.6 M	19.6 M	19.6 M	47.8 M	47.8 M	47.8 M	47.8 M	-112 M	-112 M	-112 M	-	-94.3 M	-	-	-	-82 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency